rss
Ann Rheum Dis 69:1441-1447 doi:10.1136/ard.2009.122259
  • Clinical and epidemiological research
  • Extended report

Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis

  1. Josef S Smolen1,2
  1. 1Second Department of Medicine, Hietzing Hospital, Vienna, Austria
  2. 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Austria
  3. 3Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, San Diego, California, USA
  4. 4Centocor Research and Development Inc., Malvern, Pennsylvania, USA
  1. Correspondence to Josef S Smolen, Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria; josef.smolen{at}wienkav.at
  1. Contributors JSS and DA designed the study, MS and JF performed the analyses, AK and DB collected data, MS, DA, DB, AK and JSS interpreted the data, all authors were involved in writing the paper.

  • Accepted 3 December 2009
  • Published Online First 4 June 2010

Abstract

Background and objectives Instruments for measuring disease activity in psoriatic arthritis (PsA) are not yet firmly established, and most of the currently employed ones have been derived for rheumatoid arthritis. Some of these instruments are based on 28 joint counts, which do not capture joints frequently affected in PsA. Therefore, the reliability and validity of DAREA (for ‘Disease Activity index for REactive Arthritis’), which was originally developed for reactive arthritis and employs a 66/68 joint count, was tested in patients with PsA.

Methods Trial data from the Infliximab Multinational Psoriatic Arthritis Controlled Trial were analysed. Results were then independently validated using an observational data set. DAREA was compared to other composite indices regarding correlations with core set variables, sensitivity to change and criterion validity.

Results Good correlation of the DAREA with single items of disease activity, other composite scores (r=0.6−0.9) and physical function (Health Assessment Questionnaire; r=0.5) was found. Likewise, DAREA was at least as sensitive to change as the other indices and more so in patients with distal interphalangeal joint involvement. Additionally, DAREA correlated well with radiographic changes.

Conclusion The analyses of this study provide evidence of the utility and validity of the DAREA for PsA disease activity assessment. A second name should therefore be assigned to this score: DAPSA (for ‘Disease Activity index for PSoriatic Arthritis’).

Footnotes

  • Funding This study was supported in part by the Autocure project of the European Union.

  • Competing interests DA, AK and JSS have received grant support and/or honoraria from Centocor and/or Schering-Plough, unrelated to the present study.

  • Ethics approval This study was conducted with the approval of the individual sites.

  • Provenance and peer review Not commissioned; externally peer reviewed.